Abstract
Non alcoholic fatty liver disease (NAFLD) is increasingly diagnosed worldwide and considered to be the commonest liver disorder in Western countries. It comprises a disease spectrum ranging from simple steatosis (fatty liver), through non-alcoholic steatohepatitis (NASH) to fat with fibrosis and ultimately cirrhosis. Simple steatosis is largely benign and non-progressive, whereas NASH, characterized by hepatocyte injury, inflammation and fibrosis can lead to cirrhosis, liver failure and hepatocellular carcinoma (HCC). NAFLD is strongly associated with obesity, insulin resistance, hypertension and dyslipidaemia and is now regarded as the liver manifestation of the metabolic syndrome. Rapid spread of the obesity ‘pandemic’ in adults and children, coupled with the realisation that the outcomes of obesity-related liver disease are not entirely benign, has led to rapid growth in clinical and basic studies in NAFLD over the past decade. These studies are now beginning to inform management strategies for patients with NAFLD.
Keywords: Fatty liver, Non-alcoholic steatohepatitis, metabolic syndrome, obesity, insulin resistance
Current Pharmaceutical Design
Title: Current and Future Therapeutic Strategies in NAFLD
Volume: 16 Issue: 17
Author(s): Nimantha Mark Wilfred de Alwis and Christopher Paul Day
Affiliation:
Keywords: Fatty liver, Non-alcoholic steatohepatitis, metabolic syndrome, obesity, insulin resistance
Abstract: Non alcoholic fatty liver disease (NAFLD) is increasingly diagnosed worldwide and considered to be the commonest liver disorder in Western countries. It comprises a disease spectrum ranging from simple steatosis (fatty liver), through non-alcoholic steatohepatitis (NASH) to fat with fibrosis and ultimately cirrhosis. Simple steatosis is largely benign and non-progressive, whereas NASH, characterized by hepatocyte injury, inflammation and fibrosis can lead to cirrhosis, liver failure and hepatocellular carcinoma (HCC). NAFLD is strongly associated with obesity, insulin resistance, hypertension and dyslipidaemia and is now regarded as the liver manifestation of the metabolic syndrome. Rapid spread of the obesity ‘pandemic’ in adults and children, coupled with the realisation that the outcomes of obesity-related liver disease are not entirely benign, has led to rapid growth in clinical and basic studies in NAFLD over the past decade. These studies are now beginning to inform management strategies for patients with NAFLD.
Export Options
About this article
Cite this article as:
Mark Wilfred de Alwis Nimantha and Paul Day Christopher, Current and Future Therapeutic Strategies in NAFLD, Current Pharmaceutical Design 2010; 16 (17) . https://dx.doi.org/10.2174/138161210791208901
DOI https://dx.doi.org/10.2174/138161210791208901 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelial Dysfunction and Angiogenesis in Autosomal Dominant Polycystic Kidney Disease
Current Hypertension Reviews Adherence to Treatment, Arterial Stiffness and Cognitive Function in Irbesartan- Treated Newly Diagnosed Hypertensive Patients
Current Vascular Pharmacology Cardiovascular Disease and Diabetes in South Asians: The Twin Epidemic
Current Diabetes Reviews Peripartum Cardiomyopathy: An Intriguing Challenge. Case Report with Literature Review
Current Cardiology Reviews Renal Endothelial Dysfunction in Diabetic Nephropathy
Cardiovascular & Hematological Disorders-Drug Targets Total Bakkenolides Protects Neurons Against Cerebral Ischemic Injury Through Inhibition of Nuclear Factor-κB Activation
CNS & Neurological Disorders - Drug Targets Vascular Sex Hormone Receptors and their Specific Modulators in the Management of Postmenopausal Cardiovascular Disease
Current Hypertension Reviews Effects of Subhypothermia on Ca2+, Mg2+, Excitatory Amino Acids and Plasma Endothelin in Brain Tissues of Mice with Acute Cerebral Infarction
Vascular Disease Prevention (Discontinued) Impact of Nutrition Transition and Resulting Morbidities on Economic and Human Development
Current Diabetes Reviews Combination Secondary Prevention Therapies in Vascular Diseases
Vascular Disease Prevention (Discontinued) Potential Benefits of Glitazones for Cancer and Vascular Disease
Current Drug Therapy The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease
Current Drug Targets Cardiotonic Steroids in Adaptation to Dietary Salt Intake
Current Clinical Pharmacology Translational Pharmacology in Aging Men with Benign Prostatic Hyperplasia: Molecular and Clinical Approaches to Alpha1-Adrenoceptors
Current Aging Science Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition
Reviews on Recent Clinical Trials Platelet Activation in Alzheimer’s Disease: From Pathophysiology to Clinical Value
Current Vascular Pharmacology The Diagnostic and Prognostic Value of Brain Natriuretic Peptide and Aminoterminal (nt)-pro Brain Natriuretic Peptide
Current Pharmaceutical Design Vitamin D in Chronic Kidney Disease: New Potential for Intervention
Current Drug Targets Corticosteroid as an Adjunct in the Treatment of Endobronchial Tuberculosis: A Systematic Review & Meta-analysis
Current Pediatric Reviews Physicochemical Characterization and Evaluation of Buccal Adhesive Patches Containing Propranolol Hydrochloride
Current Drug Delivery